膀胱癌:2019-2020年有什么新消息

IF 0.1 Q4 ONCOLOGY

Onkourologiya Pub Date : 2021-02-10 DOI:10.17650/1726-9776-2020-16-4-147-154

O. Karyakin

{"title":"膀胱癌:2019-2020年有什么新消息","authors":"O. Karyakin","doi":"10.17650/1726-9776-2020-16-4-147-154","DOIUrl":null,"url":null,"abstract":"This review aims to summarize the latest data on the treatment of bladder cancer published during the specified period Most of them are evidence-based and were obtained in randomized trials A new classification based on molecular data was proposed at a consensus meeting of pathologists A significant correlation has been demonstrated between life expectancy and morphological structure of the tumor This article covers chemotherapy regimens for patient with BCG (Bacillus Calmette-Guérin) intolerance Immunotherapeutic agents for muscleinvasive bladder cancer are being actively studied now;scientists are searching for the best treatment regimens with these drugs and their combinations with other antitumor agents The European Association of Urology has developed a new classification of intraoperative adverse events and recommendations for pharmacotherapy and surgical treatment of patients with bladder cancer during the COVID-19 pandemic In conclusion, the opinions of experts from the consensus meeting on the treatment of various forms of bladder cancer are given © 2020 ABC-press Publishing House All rights reserved","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bladder cancer: what’s new in 2019—2020\",\"authors\":\"O. Karyakin\",\"doi\":\"10.17650/1726-9776-2020-16-4-147-154\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This review aims to summarize the latest data on the treatment of bladder cancer published during the specified period Most of them are evidence-based and were obtained in randomized trials A new classification based on molecular data was proposed at a consensus meeting of pathologists A significant correlation has been demonstrated between life expectancy and morphological structure of the tumor This article covers chemotherapy regimens for patient with BCG (Bacillus Calmette-Guérin) intolerance Immunotherapeutic agents for muscleinvasive bladder cancer are being actively studied now;scientists are searching for the best treatment regimens with these drugs and their combinations with other antitumor agents The European Association of Urology has developed a new classification of intraoperative adverse events and recommendations for pharmacotherapy and surgical treatment of patients with bladder cancer during the COVID-19 pandemic In conclusion, the opinions of experts from the consensus meeting on the treatment of various forms of bladder cancer are given © 2020 ABC-press Publishing House All rights reserved\",\"PeriodicalId\":42924,\"journal\":{\"name\":\"Onkourologiya\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2021-02-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Onkourologiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/1726-9776-2020-16-4-147-154\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2020-16-4-147-154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本文旨在总结在特定时期内发表的膀胱癌治疗的最新数据，其中大多数是基于证据的随机试验，在病理学家共识会议上提出了基于分子数据的新分类，并证明了预期寿命与肿瘤的形态结构之间存在显著的相关性。目前正在积极研究肌肉侵袭性膀胱癌的免疫治疗药物，科学家们正在寻找这些药物的最佳治疗方案，并与其他抗肿瘤药物联合使用。欧洲泌尿外科协会制定了一项新的术中不良事件分类，并建议在2019冠状病毒病大流行期间对膀胱癌患者进行药物治疗和手术治疗。来自共识会议的专家对各种形式膀胱癌治疗的意见©2020 abc新闻出版社版权所有

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bladder cancer: what’s new in 2019—2020

This review aims to summarize the latest data on the treatment of bladder cancer published during the specified period Most of them are evidence-based and were obtained in randomized trials A new classification based on molecular data was proposed at a consensus meeting of pathologists A significant correlation has been demonstrated between life expectancy and morphological structure of the tumor This article covers chemotherapy regimens for patient with BCG (Bacillus Calmette-Guérin) intolerance Immunotherapeutic agents for muscleinvasive bladder cancer are being actively studied now;scientists are searching for the best treatment regimens with these drugs and their combinations with other antitumor agents The European Association of Urology has developed a new classification of intraoperative adverse events and recommendations for pharmacotherapy and surgical treatment of patients with bladder cancer during the COVID-19 pandemic In conclusion, the opinions of experts from the consensus meeting on the treatment of various forms of bladder cancer are given © 2020 ABC-press Publishing House All rights reserved

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Onkourologiya ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.